Código del ensayo SERENA-6 |
Ensayo A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study |
Estado Abierto a inclusión |
Localización Tumoral Mama |
Tipo de ensayo Ensayo de Fase III |
Tipo de tratamiento Tratamiento dirigido |
Situación clínica Metastásico |
Centro |